Navigation Links
KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101

JERUSALEM, Feb. 4, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, KAHR Medical Ltd. ("KAHR"), was granted a U.S. patent approval (U.S. Patent No. 8329657).  

This patent approval follows other patents already received in the U.S., Europe, Japan and Israel, protecting different combinations of KAHR's 'Signal Converting Proteins (SCPs)', which are bi-functional chimeric proteins with synergistic effects that improve the efficiency of pharmaceutical treatments. The newly issued patent protects one of KAHR's products in development, KAHR-101, which has been shown to be effective in the treatment of various cancers, arthritis and multiple sclerosis in animal models.

Ophir Shahaf , CEO of Hadasit Bio-Holdings, stated, "KAHR Medical develops ground-breaking products and we are constantly working to strengthen the company's intellectual property. The company uses a novel technology by which two therapeutic pathways can be simultaneously stimulated by a single protein drug in a synergistic manner, optimizing the care provided to patients. The completion of a recent fundraising round a few months ago will allow for further development and advancement of KAHR's drugs. We believe that in the coming year our portfolio companies will continue to present considerable clinical and business developments increasing their value as well as ours."

About KAHR Medical Ltd.

KAHR Medical is developing an innovative platform technology that produces a large number of protein-based drugs with two complementary targets. The leading products in KAHR's pipeline are designed to treat several types of cancer and diseases of the immune system. The Signal Converting Proteins (SCPs) can activate or block two biological signals in parallel, as opposed to the conventional drugs available today which address a single aspect of the disease. The original SCP technology was developed at the University of Pennsylvania and at Hadassah by the Head of the Nephrology Department, Dr. Michal Dranitzki - Elhalel. Hadasit Bio-Holdings currently holds about 55% of the company, Sanofi owns approximately 20% of the company and Thomas Eldred , owner of Recipharm (a leading European drug manufacturer), holds approximately 15%.

For more information about KAHR Medical please visit:

For more information about Hadasit Bio-Holdings please visit:

Investor Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212.896.1233 / 1239 /


SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic pain, ... at the U.S. Patent and Trademark Office (USPTO) has denied ... Patent No. 8,359,102 (the ,102 patent).  ... unit of Boston Scientific Corporation filed two petitions challenging the ...
(Date:11/30/2015)... , Nov. 30, 2015 ... the "Orphan Drugs Market 2015-2019" report ... has announced the addition of the "Orphan ... --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to their ...
(Date:11/30/2015)... global cell culture market is expected ... bn by 2022 at a CAGR of 7.1% therein. --> ... its 2013 value of US$6.1 bn to US$11.3 bn by 2022 ... Research has announced the release of a new market research study, ... ,Cell Culture Market - Global Industry Analysis, Size, Share, Growth, Trends ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... According to an article published November 13th by People ... to show her Instagram followers that the praise that they were bestowing on her ... she didn’t “want to mislead any mommy's who just had babies and are stressing,” ...
(Date:11/30/2015)... ... ... A record crowd gathered at the Pennsylvania Biotech Center of Bucks County ... Institute. , The institute, which is the research arm of the Hepatitis B Foundation, ... conference, which focused on ways companies can work to reduce the cost and improve ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their ... setting. , When you have dental problems, you need to turn to a dentist ... diagnose and treat your needs, a friendly dentist who counsels you on the best ...
(Date:11/30/2015)... ... , ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, ... Medicine in 1935. His father graduated from NYU School of Dentistry in 1965. ... as their commitment and passion to the Practice of Dentistry. Continuing the family ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
Breaking Medicine News(10 mins):